MDWD MediWound Ltd.

6.30
0  -2%
Previous Close 6.44
Open 6.40
Price To book 18.20
Market Cap 138.16M
Shares 21,930,000
Volume 54,758
Short Ratio 5.88
Av. Daily Volume 24,660

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released early February 2016. Primary endpoint met. Secondary endpoint of time to complete debridement not met. Plans to meet FDA in early 2017 to discuss Phase 3 trial.
EscharEx
Chronic and other hard-to-heal wounds
Phase 3 initiated mid April 2015. Data due 1H 2018.
NexoBrid
Severe burns

Latest News

  1. MediWound’s NexoBrid® and EscharEx® to be Highlighted in Multiple Presentations at the Symposium on Advanced Wound Care Spring
  2. MediWound Ltd. :MDWD-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
  3. MediWound Announces Conference Call and Webcast of “Meet the Experts” Panel Discussion Chaired by SunTrust Robinson Humphrey at the 49th American Burn Association Annual Meeting
  4. MediWound Ltd. :MDWD-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017
  5. MediWound’s NexoBrid® and EscharEx® to be Highlighted in Presentations at the American Burn Association 49th Annual Meeting
  6. MediWound to Present at the Oppenheimer 27th Annual Healthcare Conference
  7. Cost Analysis Demonstrating Significant Health Care Savings Utilizing NexoBrid® in Burn Management Published in BioMed Research International
  8. Edited Transcript of MDWD earnings conference call or presentation 21-Feb-17 1:30pm GMT
  9. MediWound reports 4Q loss
  10. MediWound Reports 2016 Fourth Quarter and Full Year Financial Results
  11. MediWound to Host 2016 Fourth Quarter and Full Year Financial Results Conference Call on February 21, 2017 at 8:30 a.m. Eastern Time
  12. Favorable Results from NexoBrid Phase 2 Pharmacokinetic Clinical Study Support Treatment of Severe Burns Covering up to 30% of Total Body Surface Area
  13. MediWound Initiates Second Stage of European Pediatric Phase 3 Study of NexoBrid® Expanding Treatment of Severe Burns to Children Age One to Four
  14. MediWound Reports Final Positive Results of Phase 2 Clinical Trial of EscharEx for the Debridement of Chronic and Hard-to-Heal Wounds
  15. 4 Drug Stocks Poised to Surprise this Earnings Season
  16. Why Earnings Season Could Be Great for MediWound (MDWD)
  17. Earnings Estimates Moving Higher for MediWound (MDWD): Time to Buy?
  18. Here is What Hedge Funds Think About Era Group Inc (ERA)
  19. MediWound Ltd. :MDWD-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016